Literature DB >> 31439327

Protective Effect of Alpha 1-Antitrypsin on Renal Ischemia-Reperfusion Injury.

Kye-Hwa Jeong1, Jeong-Hoon Lim1, Kyung-Hee Lee1, Min-Jung Kim1, Hee-Yeon Jung1, Ji-Young Choi1, Jang-Hee Cho1, Sun-Hee Park1, Yong-Lim Kim1, Chan-Duck Kim2.   

Abstract

BACKGROUND: α1-Antitrypsin (AAT) is an important protein in the anti-inflammatory response that functions to regulate the activity of serine proteinases. We aimed to evaluate the protective effect of AAT on ischemia-reperfusion injury (IRI) in a mouse model.
METHODS: We investigated the effects of AAT in a C57BL/6 mouse model of IRI by dividing them into 4 groups: normal control, sham operated, ischemia-reperfusion (IR), and IR after AAT pretreatment (IR-AAT). In the IR-AAT group, mice were pretreated with AAT (80 mg/kg/d) for 3 days before renal ischemia was induced by clamping the bilateral renal vascular pedicles for 30 minutes. At 24 hours after IRI, biochemistry, histology, inflammatory cytokines, and apoptosis were assayed.
RESULTS: Blood urea nitrogen and serum creatinine levels were significantly lower in the IR-AAT group than in the IR group. Neutrophil gelatinase-associated lipocalin and kidney injury molecule 1 protein levels were significantly lower in the IR-AAT group than in the IR group. In addition, there were fewer tubular injuries and less interstitial fibrosis in the IR-AAT group than in the IR group, and the expression levels of transforming growth factor β, interleukin 1β, and interleukin 6 were significantly lower in the IR-AAT group than in the IR group. When compared with the IR group, there were fewer terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay-positive cells, lower caspase 3 activity and B-cell lymphoma 2-associated X protein (Bax), and higher B-cell lymphoma 2 (Bcl-2) in the IR-AAT group.
CONCLUSIONS: α1-Antitrypsin preserved renal function, attenuated tubular injuries and interstitial fibrosis, and inhibited inflammation and apoptosis after renal IRI. Our results suggest that AAT has protective effects against renal IRI by inhibiting inflammatory and apoptosis pathways.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31439327     DOI: 10.1016/j.transproceed.2019.04.084

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  5 in total

1.  Kidney Normothermic Machine Perfusion Can Be Used as a Preservation Technique and a Model of Reperfusion to Deliver Novel Therapies and Assess Inflammation and Immune Activation.

Authors:  Azita Mellati; Letizia Lo Faro; Richard Dumbill; Pommelien Meertens; Kaithlyn Rozenberg; Sadr Shaheed; Corinna Snashall; Hannah McGivern; Rutger Ploeg; James Hunter
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

Review 2.  Fibrinolytic Serine Proteases, Therapeutic Serpins and Inflammation: Fire Dancers and Firestorms.

Authors:  Jordan R Yaron; Liqiang Zhang; Qiuyun Guo; Shelley E Haydel; Alexandra R Lucas
Journal:  Front Cardiovasc Med       Date:  2021-03-25

3.  Indirect effect of alpha-1-antitrypsin on endotoxin-induced IL-1β secretion from human PBMCs.

Authors:  Sabina Janciauskiene; Srinu Tumpara; Nils Helge Schebb; Falk F R Buettner; Malwina Mainka; Kokilavani Sivaraman; Stephan Immenschuh; Veronika Grau; Tobias Welte; Beata Olejnicka
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

4.  cMet agonistic antibody attenuates apoptosis in ischaemia-reperfusion-induced kidney injury.

Authors:  Jung Nam An; Lilin Li; Junghun Lee; Seung-Shin Yu; Jeonghwan Lee; Yong Chul Kim; Dong Ki Kim; Yun Kyu Oh; Chun Soo Lim; Yon Su Kim; Sunyoung Kim; Seung Hee Yang; Jung Pyo Lee
Journal:  J Cell Mol Med       Date:  2020-04-02       Impact factor: 5.310

5.  Renoprotective Effects of Alpha-1 Antitrypsin against Tacrolimus-Induced Renal Injury.

Authors:  Jeong-Hoon Lim; Eun-Joo Oh; Se-Hyun Oh; Hee-Yeon Jung; Ji-Young Choi; Jang-Hee Cho; Sun-Hee Park; Yong-Lim Kim; Chan-Duck Kim
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.